PDUFA Date
PDUFA Date: afrezza
- Company
- MANNKIND CORP (MNKD)
- Drug
- afrezza
- Indication
- 1 INDICATIONS AND USAGE AFREZZA ® is indicated to improve glycemic control in adult patients with diabetes mellitus. AFREZZA ® is a rapid acting inhaled human insulin indicated to improve glycemic control in adult patients with diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for the treatment of diabetic ketoacidosis (DKA) ( 1 ) Not recommended in patients who smoke or who have recently stopped smoking ( 1 ) Limitations of Use: AFREZZA is not recommended for the treatment of diabet
Other upcoming events for MNKD
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.